ArticleInternational journal of hematology2025
Therapeutic impact of mesenchymal stem cells on idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) effectively treat steroid-refractory acute graft-versus-host disease (aGVHD). However, their impact on patients with both steroid-refractory aGVHD (SR-aGVHD) and idiopathic pneumonia syndrome (IPS) is unclear. This retrospective study analyzed 24 patients who received MSCs as a secondary treatment for SR-aGVHD, including 6 who also had IPS. The 180-day overall survival rate was 52.0%, with a relapse rate of 13.3% and non-relapse mortality at 34.7%. The clinical course was compared between the six patients with concurrent IPS and SR-aGVHD who received MSCs and the 36 IPS patients who did not receive MSCs. The 6 MSC-treated patients had a higher 2-year overall survival rate than the control group, at 83.3% versus 61.1%, with all patients showing reduced oxygen requirements and improved imaging findings. Among the five patients who survived longer than 2 months after MSC therapy, the median time to complete oxygen therapy was 28 days, and steroid doses were reduced by 25% at the 2-month mark. Some patients showed improved pulmonary function after MSC therapy. These findings support MSCs as a promising treatment for SR-aGVHD and suggest potential benefits in IPS.
Indexed as
Identifiers
40489033What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.